David Jiménez, Fccp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4584203/publications.pdf

Version: 2024-02-01

248 papers 23,289 citations

50 h-index 147 g-index

267 all docs

267 docs citations

267 times ranked 18133 citing authors

#	Article	IF	CITATIONS
1	Pulmonary Embolism in Patients with COVID-19: Comparison between Different Care Settings. Seminars in Thrombosis and Hemostasis, 2023, 49, 034-046.	2.7	6
2	Consenso multidisciplinar para el manejo de la tromboembolia de pulmón. Archivos De Bronconeumologia, 2022, 58, 246-254.	0.8	12
3	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. Thrombosis and Haemostasis, 2022, 122, 131-141.	3.4	55
4	RIETE Registry: Past, Present and Future. Archivos De Bronconeumologia, 2022, 58, 205-207.	0.8	4
5	Imaging modalities for confirming pulmonary embolism during pregnancy: results from a multicenter international study. European Radiology, 2022, 32, 1238-1246.	4.5	2
6	Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism. European Respiratory Journal, 2022, 59, 2100412.	6.7	11
7	Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism. Chest, 2022, 161, 524-534.	0.8	14
8	Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial. Thrombosis and Haemostasis, 2022, 122, 857-866.	3.4	35
9	A Pulmonary Embolism Diagnostic Strategy in Patients Hospitalized for COPD Exacerbation—Reply. JAMA - Journal of the American Medical Association, 2022, 327, 184.	7.4	O
10	Association between obstructive sleep apnea and venous thromboembolism recurrence: results from a French cohort. Thrombosis Journal, 2022, 20, 1.	2.1	2
11	Prognostic impact of acute kidney injury in patients with acute pulmonary embolism data from the RIETE registry. Journal of Thrombosis and Thrombolysis, 2022, 54, 58-66.	2.1	3
12	Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry. Viruses, 2022, 14, 178.	3.3	18
13	Thromboprophylaxis in Patients With COVID-19. Chest, 2022, 162, 213-225.	0.8	58
14	Response. Chest, 2022, 161, e131-e132.	0.8	2
15	Comparison of Full-Dose vsÂModerate-Dose Systemic Thrombolysis for the Treatment of Patients With Acute Pulmonary Embolism. Chest, 2022, 162, 448-451.	0.8	1
16	Risk stratification for predicting recurrent venous thromboembolism after discontinuation of anticoagulation: a <i>post hoc</i> analysis of a French prospective multicentre study. European Respiratory Journal, 2022, 60, 2103002.	6.7	6
17	COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No. Chest, 2022, 161, 1448-1451.	0.8	6
18	Major bleeding in patients with pulmonary embolism presenting with syncope. European Journal of Clinical Investigation, 2022, , e13774.	3.4	0

#	Article	IF	Citations
19	Adjusted D-dimer cutoff levels to rule out pulmonary embolism in patients hospitalized for COPD exacerbation: results from the SLICE trial. Thrombosis Journal, 2022, 20, 10.	2.1	2
20	Significado pronóstico de los diagnósticos alternativos a la TEP hallados en la tomografÃa computarizada de tórax de pacientes ingresados por agudización de EPOC: subanálisis predefinido del ensayo SLICE. Archivos De Bronconeumologia, 2022, , .	0.8	O
21	Rebuttal From Dr David Jimenez etÂal. Chest, 2022, 161, 1453-1455.	0.8	O
22	[Translated article] Multidisciplinary consensus for the management of pulmonary thromboembolism. Archivos De Bronconeumologia, 2022, 58, T246-T254.	0.8	4
23	Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. Contemporary Clinical Trials, 2022, 115, 106714.	1.8	3
24	Ibero-American Society of Interventionism (SIDI) and the Spanish Society of Vascular and Interventional Radiology (SERVEI) Standard of Practice (SOP) for the Management of Inferior Vena Cava Filters in the Treatment of Acute Venous Thromboembolism. Journal of Clinical Medicine, 2022, 11, 77.	2.4	2
25	Effect of Prognostic Guided Management of Patients With Acute Pulmonary Embolism According to the European Society of Cardiology Risk Stratification Model. Frontiers in Cardiovascular Medicine, 2022, 9, 872115.	2.4	2
26	Statin use and 30â€day mortality in patients with acute symptomatic pulmonary embolism. Journal of Thrombosis and Haemostasis, 2022, 20, 1839-1851.	3.8	4
27	[Translated article] Prognostic Significance of Findings on CTPA Supporting an Alternative Diagnosis to PE Among Patients Hospitalized for an Exacerbation of COPD: Predefined Subanalysis of the SLICE Trial. Archivos De Bronconeumologia, 2022, 58, T412-T417.	0.8	1
28	Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study. Thrombosis Research, 2022, 214, 122-131.	1.7	3
29	Untreated obstructive sleep apnea and cardiovascular outcomes in patients with acute symptomatic pulmonary embolism. Thrombosis Research, 2022, 214, 87-92.	1.7	4
30	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA Cardiology, 2022, 7, 747.	6.1	15
31	2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncology, The, 2022, 23, e334-e347.	10.7	138
32	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	2.9	46
33	Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry. JAMA Cardiology, 2022, 7, 857.	6.1	15
34	Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000–18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. Lancet Respiratory Medicine,the, 2021, 9, 33-42.	10.7	100
35	Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019. Chest, 2021, 159, 1182-1196.	0.8	361
36	The effect of COPD on the incidence and mortality of hospitalized patients with pulmonary embolism: A nationwide population-based study (2016-2018). European Journal of Internal Medicine, 2021, 84, 18-23.	2.2	8

#	Article	IF	CITATIONS
37	Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 168-178.	2.3	10
38	Prognostic significance of computed tomography-assessed right ventricular enlargement in low-risk patients with pulmonary embolism: Systematic review and meta-analysis. Thrombosis Research, 2021, 197, 48-55.	1.7	6
39	Comparative clinical prognosis of massive and nonâ€massive pulmonary embolism: A registryâ€based cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 408-416.	3.8	12
40	Survival and quality of life after early discharge in low-risk pulmonary embolism. European Respiratory Journal, 2021, 57, 2002368.	6.7	17
41	Safety of Apixaban for Cancer-Associated Thrombosis. Thrombosis and Haemostasis, 2021, 121, 547-551.	3.4	2
42	Renal dysfunction improves risk stratification and may call for a change in the management of intermediate- and high-risk acute pulmonary embolism: results from a multicenter cohort study with external validation. Critical Care, 2021, 25, 57.	5.8	13
43	Recent Randomized Trials of Antithrombotic Therapy for PatientsÂWithÂCOVID-19. Journal of the American College of Cardiology, 2021, 77, 1903-1921.	2.8	150
44	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. JAMA - Journal of the American Medical Association, 2021, 325, 1620.	7.4	515
45	SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. Thrombosis and Haemostasis, 2021, 121, 982-991.	3.4	50
46	Impact and Role of Pulmonary Embolism Response Teams in Venous Thromboembolism Associated with Covid-19. Journal of Investigative Medicine, 2021, 69, 1153-1155.	1.6	4
47	Response. Chest, 2021, 159, 2513.	0.8	0
48	Right ventricle assessment in patients with pulmonary embolism at low risk for death based on clinical models: an individual patient data meta-analysis. European Heart Journal, 2021, 42, 3190-3199.	2.2	40
49	Bleeding risk in hospitalized patients with COVIDâ€19 receiving intermediate―or therapeutic doses of thromboprophylaxis. Journal of Thrombosis and Haemostasis, 2021, 19, 1981-1989.	3.8	42
50	The significance of heart failure in hospitalised patients with pulmonary embolism. A genderâ€specific analysis. International Journal of Clinical Practice, 2021, 75, e14558.	1.7	3
51	Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19. Journal of the American College of Cardiology, 2021, 78, 408-411.	2.8	44
52	Refinement of a modified simplified Pulmonary Embolism Severity Index for elderly patients with acute pulmonary embolism. International Journal of Cardiology, 2021, 335, 111-117.	1.7	1
53	Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial. European Heart Journal, 2021, 42, 3146-3157.	2.2	64
54	Multidisciplinary consensus for the management of pulmonary thromboembolism. Archivos De Bronconeumologia, $2021, \ldots$	0.8	0

#	Article	IF	CITATIONS
55	Respuesta a "Consenso multidisciplinar, ¿falta alguien?― Archivos De Bronconeumologia, 2021, 57, 612.	0.8	1
56	Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism. Journal of the American Heart Association, 2021, 10, e021467.	3.7	4
57	Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. Lancet Haematology,the, 2021, 8, e627-e636.	4.6	11
58	Spanish consensus for the management of pulmonary thromboembolism. Archivos De Bronconeumologia, 2021, 57, 612.	0.8	0
59	Sex-differences in the effect of obstructive sleep apnea on patients hospitalized with pulmonary embolism and on in-hospital mortality. Scientific Reports, 2021, 11, 18390.	3.3	2
60	Systematic testing for venous thromboembolism in hospitalized patients with COVID-19 and raised D-dimer levels. Thrombosis Update, 2021, 2, 100029.	0.9	8
61	Presenting Characteristics, Treatment Patterns, and Outcomes among Patients with Venous Thromboembolism during Hospitalization for COVID-19. Seminars in Thrombosis and Hemostasis, 2021, 47, 351-361.	2.7	34
62	Prognostic Impact of Obstructive Sleep Apnea in Patients Presenting with Acute Symptomatic Pulmonary Embolism. Thrombosis and Haemostasis, 2021, 121, 808-815.	3.4	12
63	Clinical characteristics and 3-month outcomes in cancer patients with incidental <i>versus</i> clinically suspected and confirmed pulmonary embolism. European Respiratory Journal, 2021, 58, 2002723.	6.7	9
64	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. Journal of the American College of Cardiology, 2021, 78, 1635-1654.	2.8	42
65	PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19. Viruses, 2021, 13, 2128.	3.3	4
66	Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation. JAMA - Journal of the American Medical Association, 2021, 326, 1277.	7.4	28
67	Profiles of patients with venous thromboembolic disease in the emergency department and their medium-term prognosis: data from the ESPHERIA registry. Emergencias, 2021, 33, 107-114.	0.6	0
68	A Comparison of GFR Calculated by Cockcroft-Gault vs. MDRD Formula in the Prognostic Assessment of Patients with Acute Pulmonary Embolism. Disease Markers, 2021, 2021, 1-9.	1.3	1
69	Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. European Heart Journal, 2020, 41, 509-518.	2.2	106
70	Pulmonary embolism in Europe remains a cause of concern despite declining deaths. Lancet Respiratory Medicine, the, 2020, 8, 222-224.	10.7	4
71	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal, 2020, 41, 543-603.	2.2	2,426
72	Atrial fibrillation in the course of pulmonary embolism: just a little smoke, or fuel to the fire?. Journal of Internal Medicine, 2020, 287, 114-116.	6.0	5

#	Article	IF	Citations
73	Systolic blood pressure and mortality in acute symptomatic pulmonary embolism. International Journal of Cardiology, 2020, 302, 157-163.	1.7	13
74	Necesidad de una ecocardiografÃa transtorácica en pacientes con tromboembolia de pulmón de riesgo bajo: revisión sistemática y metanálisis. Archivos De Bronconeumologia, 2020, 56, 306-313.	0.8	5
75	ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. European Journal of Internal Medicine, 2020, 82, 48-55.	2.2	5
76	ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3Âmonths. Thrombosis Research, 2020, 196, 297-304.	1.7	5
77	Changing Trends in Hospital Admissions for Pulmonary Embolism in Spain from 2001 to 2018. Journal of Clinical Medicine, 2020, 9, 3221.	2.4	7
78	Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: the BACS score. European Respiratory Journal, 2020, 56, 2002336.	6.7	30
79	Real-Time Dissemination of Aggregate Data on Presentation and Outcomes of Patients With Venous Thromboembolism: The RIETE Infographics Project. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962093120.	1.7	1
80	Duración de la anticoagulación tras una tromboembolia de pulmón: una decisión no siempre sencilla. Archivos De Bronconeumologia, 2020, 56, 617-618.	0.8	0
81	Association between reperfusion therapy and outcomes in patients with acute pulmonary embolism and right heart thrombi. European Respiratory Journal, 2020, 56, 2000538.	6.7	6
82	Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019. Chest, 2020, 158, 1143-1163.	0.8	531
83	Outcomes after Vena Cava Filter Use in Patients with Cancer-Associated Venous Thromboembolism and Contraindications to Anticoagulation. Thrombosis and Haemostasis, 2020, 120, 1035-1044.	3.4	10
84	Patient-Level, Institutional, and Temporal Variations in Use of Imaging Modalities to Confirm Pulmonary Embolism. Circulation: Cardiovascular Imaging, 2020, 13, e010651.	2.6	8
85	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis, 2020, 120, 1004-1024.	3.4	206
86	Outcome of patients with acute symptomatic pulmonary embolism and psychiatric disorders. Thrombosis Research, 2020, 193, 90-97.	1.7	3
87	Clinical conundrum: concomitant high-risk pulmonary embolism and acute ischemic stroke. Emergency Radiology, 2020, 27, 433-439.	1.8	7
88	Recent trends in use of inferior vena caval filters in US older adults with acute pulmonary embolism. Thrombosis Research, 2020, 186, 78-79.	1.7	2
89	Need for Transthoracic Echocardiogram in Patients with Low-Risk Pulmonary Thromboembolism: A Systematic Review and Meta-Analysis. Archivos De Bronconeumologia, 2020, 56, 306-313.	0.8	5
90	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology, 2020, 75, 2950-2973.	2.8	2,392

#	Article	IF	CITATIONS
91	Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. Thrombosis Research, 2020, 196, 382-394.	1.7	62
92	Implications of Abnormal Troponin Levels With Normal Right Ventricular Function in Normotensive Patients With Acute Pulmonary Embolism. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962096776.	1.7	2
93	Cardiovascular mortality and morbidity in pulmonary embolism. , 2020, , 184-197.		O
94	Participaci \tilde{A}^3 n de los equipos de respuesta r \tilde{A}_i pida de tromboembolia pulmonar durante el perioperatorio. Archivos De Cardiologia De Mexico, 2020, 90, 321-327.	0.2	1
95	Clinical characteristics and course in emergency department patients with chronic obstructive pulmonary disease and symptomatic acute venous thromboembolic disease: secondary analysis of the ESPHERIA registry. Emergencias, 2020, 32, 40-44.	0.6	O
96	The Role of the Pulmonologist in a Pulmonary Embolism Response Team (PERT): A Time to Come on Stage. Archivos De Bronconeumologia, 2019, 55, 1-2.	0.8	1
97	Cardiopulmonary exercise testing with ventilatory gas analysis for evaluation of chronic thromboembolic pulmonary hypertension: Unmasking its role after a therapeuthic intervention. International Journal of Cardiology, 2019, 296, 155-156.	1.7	2
98	Hospital volume and outcomes for acute pulmonary embolism: multinational population based cohort study. BMJ: British Medical Journal, 2019, 366, l4416.	2.3	41
99	Pulmonary Embolism Hospitalization, Readmission, and Mortality Rates in US Older Adults, 1999-2015. JAMA - Journal of the American Medical Association, 2019, 322, 574.	7.4	69
100	Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro) Tj ETQq0 0 0 rgBT 2019, 45, 793-801.	/Overlock 2.7	10 Tf 50 387
101	Pulmonary Embolism Response Teams: Pursuing Excellence in the Care for Venous Thromboembolism. Archives of Medical Research, 2019, 50, 257-258.	3.3	9
102	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Respiratory Journal, 2019, 54, 1901647.	6.7	806
103	Risk adapted management of acute pulmonary embolism in women. Thrombosis Research, 2019, 181, S29-S32.	1.7	3
104	The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease. Clinical Cardiology, 2019, 42, 346-351.	1.8	9
105	Hemopericardium and Cardiac Tamponade as a Complication of Vena Caval Filters: Systematic Review of the Published Literature and the MAUDE Database. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961984911.	1.7	2
106	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELDâ€√TE patients. Journal of Thrombosis and Haemostasis, 2019, 17, 1694-1706.	3.8	30
107	Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism. Internal and Emergency Medicine, 2019, 14, 1101-1112.	2.0	9
108	Highlights from the ERS International Congress 2018: Assembly 13 – Pulmonary Vascular Diseases. ERJ Open Research, 2019, 5, 00202-2018.	2.6	0

#	Article	IF	CITATIONS
109	Catheter-directed aspiration thrombectomy and low-dose thrombolysis for patients with acute unstable pulmonary embolism: Prospective outcomes from a PE registry. International Journal of Cardiology, 2019, 287, 106-110.	1.7	22
110	Assembly 13: placing the pulmonary circulation in the heart of ERS. Breathe, 2019, 15, 88-89.	1.3	1
111	Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries. Quality of Life Research, 2019, 28, 2111-2124.	3.1	38
112	Comparison of All-Cause Mortality Following VTE Treatment Between Propensity Score-Adjusted Observational Studies and Matched Randomized Controlled Trials. Chest, 2019, 155, 689-698.	0.8	7
113	Pulmonary embolism response teams: Purpose, evidence for efficacy, and future research directions. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 769.	2.3	7
114	Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years. Scientific Reports, 2019, 9, 20064.	3.3	5
115	Intermediate-High Risk Pulmonary Embolism. TH Open, 2019, 03, e356-e363.	1.4	23
116	Accuracy and Interobserver Reliability of the Simplified Pulmonary Embolism Severity Index Versus the Hestia Criteria for Patients With Pulmonary Embolism. Academic Emergency Medicine, 2019, 26, 394-401.	1.8	16
117	The Role of the Pulmonologist in a Pulmonary Embolism Response Team (PERT): A Time to Come on Stage. Archivos De Bronconeumologia, 2019, 55, 1-2.	0.8	1
118	The Prognostic Value of Renal Function in Acute Pulmonary Embolism—A Multi-Centre Cohort Study. Thrombosis and Haemostasis, 2019, 119, 140-148.	3.4	24
119	Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry. European Respiratory Journal, 2019, 53, 1801677.	6.7	13
120	Incomplete echocardiographic recovery at 6Âmonths predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Clinical Research in Cardiology, 2019, 108, 772-778.	3.3	44
121	Meta-Analysis of Prevalence and Short-Term Prognosis of Hemodynamically Unstable Patients With Symptomatic Acute Pulmonary Embolism. American Journal of Cardiology, 2019, 123, 684-689.	1.6	36
122	Obstructive sleep apnoea and venous thromboembolism: pathophysiological links and clinical implications. European Respiratory Journal, 2019, 53, 1800893.	6.7	31
123	Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism. JAMA Internal Medicine, 2019, 179, 263.	5.1	9
124	Sex Differences in Risk Factors, Clinical Presentation, Treatment and Outcomes of Patients Presenting with Acute Pulmonary Embolism. Blood, 2019, 134, 2429-2429.	1.4	2
125	Assessment of coexisting deep vein thrombosis for risk stratification of acute pulmonary embolism. Thrombosis Research, 2018, 164, 40-44.	1.7	12
126	Risk stratification of acute pulmonary embolism based on clinical parameters, H-FABP and multidetector CT. International Journal of Cardiology, 2018, 265, 223-228.	1.7	13

#	Article	IF	CITATIONS
127	A prospective validation of the Bova score in normotensive patients with acute pulmonary embolism. Thrombosis Research, 2018, 165, 107-111.	1.7	35
128	Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. Thrombosis Research, 2018, 170, 181-191.	1.7	29
129	Surrogate Endpoints for Pulmonary Hypertension Management and Trial Design. Journal of the American College of Cardiology, 2018, 71, 764-765.	2.8	1
130	Evaluación clÃnica frente a escalas estandarizadas para el pronóstico de los pacientes con tromboembolia pulmonar aguda sintomática. Medicina ClĀnica, 2018, 151, 136-140.	0.6	10
131	Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). Thrombosis and Haemostasis, 2018, 118, 214-224.	3.4	160
132	Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study. Thrombosis Journal, 2018, 16, 9.	2.1	15
133	Prognostic impact of copeptin in pulmonary embolism: a multicentre validation study. European Respiratory Journal, 2018, 51, 1702037.	6.7	30
134	$\tilde{A}\%$ xito en la recuperaci \tilde{A}^3 n de filtro de vena cava inferior opcional: An \tilde{A}_i lisis de 246 pacientes. Archivos De Bronconeumologia, 2018, 54, 371-377.	0.8	4
135	Enfermedad tromboemb $ ilde{A}^3$ lica venosa y c $ ilde{A}_i$ ncer: un reto para los cl $ ilde{A}$ nicos. Archivos De Bronconeumologia, 2018, 54, 359-360.	0.8	1
136	Performance of Early Prognostic Assessment Independently Predicts the Outcomes in Patients with Acute Pulmonary Embolism. Thrombosis and Haemostasis, 2018, 47, 798-800.	3.4	5
137	Systematic review of efficacy and safety of retrievable inferior vena caval filters. Thrombosis Research, 2018, 165, 79-82.	1.7	10
138	Sex Differences in Patients With Occult Cancer After Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 489-495.	1.7	6
139	Pulmonary embolism severity assessment and prognostication. Thrombosis Research, 2018, 163, 246-251.	1.7	13
140	Outpatient therapy for acute symptomatic pulmonary embolism diagnosed in the emergency department: Time to improve the evidence base. Thrombosis Research, 2018, 161, 117-118.	1.7	3
141	Diclofenac for reversal of right ventricular dysfunction in acute normotensive pulmonary embolism: A pilot study. Thrombosis Research, 2018, 162, 1-6.	1.7	5
142	Efficacy and safety outcomes of recanalisation procedures in patients with acute symptomatic pulmonary embolism: systematic review and network meta-analysis. Thorax, 2018, 73, 464-471.	5.6	33
143	Outcomes beyond the Third Month of Anticoagulation in Patients Aged >75 Years with a First Episode of Unprovoked Venous Thromboembolism. TH Open, 2018, 02, e428-e436.	1.4	3
144	Clinical gestalt versus prognostic scores for prognostication of patients with acute symptomatic pulmonary embolism. Medicina ClÃnica (English Edition), 2018, 151, 136-140.	0.2	1

#	Article	IF	Citations
145	Differential impact of syncope on the prognosis of patients with acute pulmonary embolism: a systematic review and meta-analysis. European Heart Journal, 2018, 39, 4186-4195.	2.2	55
146	Thirty-day outcomes in patients with acute pulmonary embolism who discontinued anticoagulant therapy before 90 days. American Heart Journal, 2018, 206, 1-10.	2.7	10
147	Early Use of Echocardiography in Patients With Acute Pulmonary Embolism: Findings From the RIETE Registry. Journal of the American Heart Association, 2018, 7, e009042.	3.7	31
148	Venous Thromboembolic Disease and Cancer: A Challenge for Clinicians. Archivos De Bronconeumologia, 2018, 54, 359-360.	0.8	0
149	Success in Optional Vena Cava Filter Retrieval. An Analysis of 246 Patients. Archivos De Bronconeumologia, 2018, 54, 371-377.	0.8	6
150	Scores to Identify Occult Cancer in Venous Thromboembolism: Do They Work?. Thrombosis and Haemostasis, 2018, 118, 1343-1344.	3.4	1
151	Epidemiology, patterns of care and mortality for patients with hemodynamically unstable acute symptomatic pulmonary embolism. International Journal of Cardiology, 2018, 269, 327-333.	1.7	41
152	Management appropriateness and outcomes of patients with acute pulmonary embolism. European Respiratory Journal, 2018, 51, 1800445.	6.7	33
153	Aggressive Treatment of Intermediate-Risk Patients with Acute Symptomatic Pulmonary Embolism. Clinics in Chest Medicine, 2018, 39, 569-581.	2.1	8
154	Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism. PLoS ONE, 2018, 13, e0194673.	2.5	16
155	Comparison of clinical scores for identification of patients with pulmonary embolism at intermediate–high risk of adverse clinical outcome: the prognostic role of plasma lactate. Internal and Emergency Medicine, 2017, 12, 657-665.	2.0	33
156	Assessment of right ventricular function in acute pulmonary embolism. American Heart Journal, 2017, 185, 123-129.	2.7	30
157	Risk Stratification for Proven Acute Pulmonary Embolism: What Information Is Needed?. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 011-017.	2.1	11
158	Catheter-Based Approaches for the Treatment of Acute Pulmonary Embolism. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 073-083.	2.1	10
159	Response. Chest, 2017, 151, 728-729.	0.8	1
160	Prognostic Scores for Acute Pulmonary Embolism. Seminars in Thrombosis and Hemostasis, 2017, 43, 486-492.	2.7	7
161	Impact of Thrombolytic Therapy onÂtheÂLong-Term Outcome of Intermediate-Risk PulmonaryÂEmbolism. Journal of the American College of Cardiology, 2017, 69, 1536-1544.	2.8	258
162	Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism. American Journal of Medicine, 2017, 130, 588-595.	1.5	45

#	Article	IF	CITATIONS
163	CaracterÃsticas clÃnicas y pronÃ ³ stico de la tromboembolia pulmonar secundaria al sÃndrome de clase turista. Archivos De Bronconeumologia, 2017, 53, 495-500.	0.8	1
164	The Reply. American Journal of Medicine, 2017, 130, e271.	1.5	0
165	Clinical Characteristics and Prognosis of Pulmonary Embolism Caused by Economy Class Syndrome. Archivos De Bronconeumologia, 2017, 53, 495-500.	0.8	3
166	Prognostic value of right ventricular dilatation in patients with low-risk pulmonary embolism. European Respiratory Journal, 2017, 50, 1701611.	6.7	35
167	Prognostic Significance of Right Heart Thrombi in Patients With Acute Symptomatic Pulmonary Embolism. Chest, 2017, 151, 409-416.	0.8	65
168	Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. Chest, 2017, 151, 564-571.	0.8	51
169	Clinical Prognosis of Nonmassive Central and Noncentral Pulmonary Embolism. Chest, 2017, 151, 829-837.	0.8	21
170	Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study. Thrombosis and Haemostasis, 2017, 117, 2425-2434.	3.4	9
171	Impact of obstructive sleep apnea on cardiovascular outcomes in patients with acute symptomatic pulmonary embolism: Rationale and methodology for the POPE study. Clinical Cardiology, 2017, 40, 1182-1188.	1.8	13
172	Sex differences in the characteristics and short-term prognosis of patients presenting with acute symptomatic pulmonary embolism. PLoS ONE, 2017, 12, e0187648.	2.5	39
173	Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Thrombosis and Haemostasis, 2016, 116, 191-197.	3.4	38
174	Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism. European Respiratory Journal, 2016, 48, 1360-1368.	6.7	21
175	Right heart thrombi in pulmonary embolism. European Respiratory Journal, 2016, 48, 1377-1385.	6.7	58
176	National Consensus on the Diagnosis, Risk Stratification and Treatment of Patients with Pulmonary Embolism: An Update. Archivos De Bronconeumologia, 2016, 52, 61-62.	0.8	0
177	DVT Management andÂOutcome Trends, 2001 to 2014. Chest, 2016, 150, 374-383.	0.8	23
178	Type 2 diabetes is associated with a higher incidence of hospitalization for pulmonary embolism in Spain: Analysis of hospital discharge data during 2004–2013. Respirology, 2016, 21, 1277-1284.	2.3	16
179	Multidetector computed tomographic pulmonary angiography in patients with a high clinical probability of pulmonary embolism. Journal of Thrombosis and Haemostasis, 2016, 14, 114-120.	3.8	28
180	Comparison of Four Bleeding Risk Scores to Identify Rivaroxabanâ€treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding. Academic Emergency Medicine, 2016, 23, 144-150.	1.8	25

#	Article	IF	CITATIONS
181	Outcomes Associated With Inferior Vena Cava Filters Among Patients With Thromboembolic Recurrence During Anticoagulant Therapy. JACC: Cardiovascular Interventions, 2016, 9, 2440-2448.	2.9	31
182	Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score. Thrombosis and Haemostasis, 2016, 115, 827-834.	3.4	30
183	Risk Stratification of Patients With Acute Symptomatic Pulmonary Embolism Based on Presence or Absence of Lower Extremity DVT. Chest, 2016, 149, 192-200.	0.8	76
184	Risk stratification of patients with acute symptomatic pulmonary embolism. Internal and Emergency Medicine, 2016, 11, 11-18.	2.0	39
185	Pulmonary embolism, acute coronary syndrome and ischemic stroke in the Spanish National Discharge Database. European Journal of Internal Medicine, 2016, 28, 65-69.	2.2	11
186	Clinical significance and management of right heart thrombi: more questions than answers. European Respiratory Journal, 2016, 47, 702-703.	6.7	4
187	Trends in the Management and Outcomes of Acute Pulmonary Embolism. Journal of the American College of Cardiology, 2016, 67, 162-170.	2.8	271
188	Antithrombotic Therapy for VTE Disease. Chest, 2016, 149, 315-352.	0.8	4,060
189	Actualización del Consenso nacional sobre el diagnóstico, estratificación de riesgo y tratamiento de los pacientes con tromboembolia de pulmón. Archivos De Bronconeumologia, 2016, 52, 61-62.	0.8	4
190	Validation of a Model for Identification of Patients at Intermediate to High Risk for Complications Associated With Acute Symptomatic Pulmonary Embolism. Chest, 2015, 148, 211-218.	0.8	85
191	Controversies in the Management of Life-Threatening Pulmonary Embolism. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 835-841.	2.1	16
192	Risk assessment and management of high and intermediate risk pulmonary embolism. Presse Medicale, 2015, 44, e401-e408.	1.9	7
193	Short-term clinical outcome of normotensive patients with acute PE and high plasma lactate. Thorax, 2015, 70, 333-338.	5.6	55
194	Identification of Low-Risk Patients with Acute Symptomatic Pulmonary Embolism for Outpatient Therapy. Annals of the American Thoracic Society, 2015, 12, 150626095350002.	3.2	27
195	Outpatient Management Eligibility Criteria for Patients Who Have Acute Symptomatic Pulmonary Embolism. Annals of the American Thoracic Society, 2015, 12, 623-624.	3.2	2
196	Age-adjusted high-sensitivity troponin T cut-off value for risk stratification of pulmonary embolism. European Respiratory Journal, 2015, 45, 1323-1331.	6.7	34
197	Identification of Reduced Circulating Haptoglobin Concentration as a Biomarker of the Severity of Pulmonary Embolism: A Nontargeted Proteomic Study. PLoS ONE, 2014, 9, e100902.	2.5	19
198	Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. European Respiratory Journal, 2014, 43, 1669-1677.	6.7	121

#	Article	IF	Citations
199	Prognostic significance of multidetector CT in normotensive patients with pulmonary embolism: results of the protect study. Thorax, 2014, 69, 109-115.	5.6	61
200	Hipertensi \tilde{A}^3 n pulmonar tromboemb \tilde{A}^3 lica cr \tilde{A}^3 nica: la experiencia mejora los resultados. Archivos De Bronconeumologia, 2014, 50, 507-508.	0.8	0
201	Interobserver reliability of echocardiography for prognostication of normotensive patients with pulmonary embolism. Cardiovascular Ultrasound, 2014, 12, 29.	1.6	40
202	Pulmonary embolism: current and new treatment options. Current Medical Research and Opinion, 2014, 30, 1975-1989.	1.9	11
203	Trends in hospital admissions for pulmonary embolism in Spain from 2002 to 2011. European Respiratory Journal, 2014, 44, 942-950.	6.7	88
204	Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. European Respiratory Journal, 2014, 44, 694-703.	6.7	186
205	Reply. Journal of the American College of Cardiology, 2014, 64, 955-956.	2.8	9
206	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2014, 35, 3033-3080.	2.2	2,591
207	Survival Effects of Inferior Vena Cava FilterÂinÂPatients With Acute Symptomatic Venous Thromboembolism and a Significant Bleeding Risk. Journal of the American College of Cardiology, 2014, 63, 1675-1683.	2.8	167
208	Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. New England Journal of Medicine, 2014, 370, 1402-1411.	27.0	1,221
209	Derivation and Validation of Multimarker Prognostication for Normotensive Patients with Acute Symptomatic Pulmonary Embolism. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 718-726.	5.6	164
210	National Consensus on the Diagnosis, Risk Stratification and Treatment of Patients with Pulmonary Embolism. Archivos De Bronconeumologia, 2013, 49, 534-547.	0.8	9
211	Validación de 2 escalas clÃnicas pronósticas en pacientes con tromboembolia pulmonar aguda sintomática. Archivos De Bronconeumologia, 2013, 49, 427-431.	0.8	12
212	Consenso nacional sobre el diagn \tilde{A}^3 stico, estratificaci \tilde{A}^3 n de riesgo y tratamiento de los pacientes con tromboembolia pulmonar. Archivos De Bronconeumologia, 2013, 49, 534-547.	0.8	70
213	Validation of Two Clinical Prognostic Models in Patients With Acute Symptomatic Pulmonary Embolism. Archivos De Bronconeumologia, 2013, 49, 427-431.	0.8	11
214	Point: Should Systemic Lytic Therapy Be Used for Submassive Pulmonary Embolism? Yes. Chest, 2013, 143, 296-299.	0.8	14
215	Early discharge and outpatient treatment of patients admitted for acute pulmonary embolism. European Respiratory Journal, 2013, 41, 487-488.	6.7	2
216	Changes in PESI scores predict mortality in intermediate-risk patients with acute pulmonary embolism. European Respiratory Journal, 2013, 41, 354-359.	6.7	34

#	Article	IF	Citations
217	A Clinical Prognostic Model for the Identification of Low-Risk Patients With Acute Symptomatic Pulmonary Embolism and Active Cancer. Chest, 2013, 143, 138-145.	0.8	58
218	Rebuttal From Dr Jiménez. Chest, 2013, 143, 302-303.	0.8	0
219	Prognostic Scores in Pulmonary Embolism: Response. Chest, 2013, 143, 873.	0.8	0
220	Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. Thrombosis and Haemostasis, 2013, 110, 834-843.	3.4	94
221	A Strategy Combining Imaging and Laboratory Biomarkers in Comparison With a Simplified Clinical Score for Risk Stratification of Patients With Acute Pulmonary Embolism. Chest, 2012, 141, 916-922.	0.8	7 5
222	Prognostic significance of multidetector computed tomography in normotensive patients with pulmonary embolism: rationale, methodology and reproducibility for the PROTECT study. Journal of Thrombosis and Thrombolysis, 2012, 34, 187-192.	2.1	31
223	Apixaban: an Oral Direct Factor-Xa Inhibitor. Advances in Therapy, 2012, 29, 187-201.	2.9	23
224	Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism. Thorax, 2011, 66, 75-81.	5.6	115
225	Echocardiographic assessment of pulmonary arterial pressure in the follow-up of patients with pulmonary embolism. Thrombosis Research, 2011, 127, 303-308.	1.7	45
226	Prognostic importance of anaemia in patients with acute pulmonary embolism. Thrombosis and Haemostasis, 2011, 106, 289-295.	3.4	15
227	A comparison of the original and simplified Pulmonary Embolism Severity Index. Thrombosis and Haemostasis, 2011, 106, 423-428.	3.4	50
228	Predictive Value of the High-Sensitivity Troponin T Assay and the Simplified Pulmonary Embolism Severity Index in Hemodynamically Stable Patients With Acute Pulmonary Embolism. Circulation, 2011, 124, 2716-2724.	1.6	219
229	Mortality-Risk Profiling using Doppler Leg Scans in Patients with Pulmonary Embolism. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 856-857.	5.6	0
230	Risk stratification of normotensive patients with acute symptomatic pulmonary embolism. British Journal of Haematology, 2010, 151, 415-424.	2.5	72
231	Prognostic Significance of Deep Vein Thrombosis in Patients Presenting with Acute Symptomatic Pulmonary Embolism. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 983-991.	5.6	154
232	Prognostication of Pulmonary Embolism. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1096-1097.	5.6	1
233	Simplification of the Pulmonary Embolism Severity Index for Prognostication in Patients With Acute Symptomatic Pulmonary Embolism. Archives of Internal Medicine, 2010, 170, 1383.	3.8	959
234	Incidence of Symptomatic and Asymptomatic Chronic Thromboembolic Pulmonary Hypertension. Archivos De Bronconeumologia, 2010, 46, 628-633.	0.8	40

#	Article	IF	Citations
235	Home treatment in pulmonary embolism. Thrombosis Research, 2010, 126, e1-e5.	1.7	111
236	Association of anaemia and mortality in patients with acute pulmonary embolism. Thrombosis and Haemostasis, 2009, 102, 153-158.	3.4	21
237	Weekend Versus Weekday Admission and Mortality After Acute Pulmonary Embolism. Circulation, 2009, 119, 962-968.	1.6	150
238	Troponin-Based Risk Stratification of Patients With Acute Nonmassive Pulmonary Embolism. Chest, 2009, 136, 974-982.	0.8	179
239	The \hat{I}^2 \hat{I}_\pm -Encoders for Robust A/D Conversion. Acta Applicandae Mathematicae, 2009, 107, 313-323.	1.0	O
240	Chronic Obstructive Pulmonary Disease in Patients With Acute Symptomatic Pulmonary Embolism. Archivos De Bronconeumologia, 2009, 45, 286-290.	0.8	14
241	Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Current Opinion in Pulmonary Medicine, 2008, 14, 414-421.	2.6	47
242	Short-term clinical outcome after acute symptomatic pulmonary embolism. Thrombosis and Haemostasis, 2008, 100, 937-942.	3.4	54
243	Short-term clinical outcome after acute symptomatic pulmonary embolism. Thrombosis and Haemostasis, 2008, 100, 937-42.	3.4	11
244	Prognostic Models for Selecting Patients With Acute Pulmonary Embolism for Initial Outpatient Therapy. Chest, 2007, 132, 24-30.	0.8	168
245	A propósito de: "¿Puede reducir la mortalidad de los pacientes con EPOC la profilaxis domiciliaria de la enfermedad tromboembólica venosa?― Archivos De Bronconeumologia, 2007, 43, 523-524.	0.8	2
246	Pulmonary Embolism in Patients with Chronic Obstructive Pulmonary Disease or Congestive Heart Failure. American Journal of Medicine, 2006, 119, 851-858.	1.5	68
247	Incidence of Air Travel–Related Pulmonary Embolism at the Madrid-Barajas Airport. Archives of Internal Medicine, 2003, 163, 2766.	3.8	120
248	Sex as a prognostic factor for mortality in adults with acute symptomatic pulmonary embolism. The Cochrane Library, 0 , , .	2.8	1